相关实验视频

Updated: Jul 1, 2025

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

针对ECE-1的siRNA部分逆转了单类模型中的肺动脉高血压相关损伤

Citlali Margarita Blancas-Napoles¹, Sandra Edith Cabrera-Becerra¹, Vivany Maydel Sierra-Sánchez¹

¹Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México, México.

Current molecular pharmacology

|March 11, 2024

概括

这项研究开发了一种用于肺动脉高血压 (PAH) 的新型治疗方法,使用小干扰RNA (siRNAs) 向内甲蛋白-1. 在大鼠模型中,siRNA疗法有效地降低了PAH的关键标志物,提供了一个有前途的治疗方法.

科学领域:

心血管研究研究心血管研究
分子医学是分子医学.
在RNA治疗方面,RNA疗法.

背景情况:

肺动脉高血压 (PAH) 是一种严重的疾病,其特点是肺动脉压升高.
增加内甲蛋白-1的产生有助于血管抵抗和PAH的右心室缩.
目前对PAH的治疗方法有限,需要新的治疗策略.

研究的目的:

设计,合成和评估两个小干扰RNA (siRNAs) 向内甲蛋白-1的有效性.
评估这些siRNAs的治疗潜力,在单克罗他林诱导的肺动脉高血压 (PAH) 的小鼠模型中.

主要方法:

肺动脉高血压 (PAH) 在Wistar大鼠中被诱导使用单克罗他林.
大鼠接受了针对endothelin-1的siRNA治疗,在单核类药物给药后两周.
评估包括右心室缩 (RV/LV+S比),血压,体重,以及通过RT-PCR进行内甲蛋白转化酶-1 (ECE-1) mRNA表达.

主要成果:

莫诺克罗塔林诱导的PAH大鼠表现出增加的ECE-1mRNA和右心室缩.
siRNA治疗显著降低了ECE-1 mRNA表达和右心室缩.
与对照组相比,siRNA组的体重也显著下降.

结论:

在大鼠模型中,针对ECE-1的siRNAs的使用有效地减轻了PAH相关的损害.
这项研究强调了基于siRNA的策略治疗肺动脉高血压的治疗潜力.
用siRNA准内甲蛋白-1代表了开发PAH治疗的有希望的途径.

关键词:

输内甲林-1-1是什么恩多林-1转化酶的转化酶.末端蛋白-1.1,可以使用.单克罗他林 (Monocrotaline) 是一种可怕的药物.肺动脉高血压是肺动脉高血压.小的干扰RNA可以干扰RNA.

更多相关视频

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...